SOHO 2025 | How advances in molecular sequencing technologies have shaped ALL therapy
In this video, Sarah Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, briefly comments on the impact that advances in molecular sequencing technologies have had on the treatment of Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL). This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So 15 years ago we had no idea who these patients were because all we had was conventional cytogenetics and FISH, and so with the advent of next-generation sequencing technologies that have become a lot more sophisticated, faster, and also more cost-effective, we are really much better able to identify these patients more quickly and certainly more precisely. I think that this has been a game-changer and one of the most exciting advances, certainly in ALL, in trying to understand who these patients are and giving them better opportunities for tailored therapies...
So 15 years ago we had no idea who these patients were because all we had was conventional cytogenetics and FISH, and so with the advent of next-generation sequencing technologies that have become a lot more sophisticated, faster, and also more cost-effective, we are really much better able to identify these patients more quickly and certainly more precisely. I think that this has been a game-changer and one of the most exciting advances, certainly in ALL, in trying to understand who these patients are and giving them better opportunities for tailored therapies. Identifying who these patients are through next-generation sequencing fusion panels or RNA sequencing helps us to add targeted therapies much more quickly, early in the frontline and potentially improve outcomes. And also with the intercalation of immunotherapies into them, really regardless of what their genetics are, we’re able to achieve better end-induction MRD responses.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
